printemailclick to share buttonfacebooktwitterlinkedin
Sarcoma Evidence-based Series (EBS) and Practice Guidelines (PG)
 

Sarcoma includes cancers of muscle, bone and soft tissues.

The Sarcoma Disease Site Group (Sarcoma DSG) produces evidence-based reports to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances. Reports produced by this group are available below.

The PEBC has a formal and standardized process to ensure the currency of each document. This process guides clinical experts to assess a document’s current status and relevance (please see the PEBC Assessment & Review Protocol for more information). A final status statement is added to the document when this review process is complete. The current status of each guidance document is noted beside the title and link as outlined below:

  • Documents listed as CURRENT are 3 years old or less, up-to-date, and can be used for decision making.
  • Documents listed as IN REVIEW are undergoing assessment for currency and relevance.  The DSG/GDG has determined that it is still appropriate for this document to continue to be available while this updating process unfolds.
  • Documents that are listed as “FOR EDUCATION AND INFORMATION PURPOSES” are documents for which no further updates are planned and whose recommendations may no longer be consistent with recent evidence.  They may be of educational, historical, clinical, or system interest.

If you have any questions regarding a document that is “In Review,” please contact the PEBC (ccopgi@mcmaster.ca) or the lead author of the document.

  • Optimal Treatment Strategies for Localized Ewing’s Scarcoma of Bone after Neoadjuvant Chemotherapy
    Guideline 11-6: December 2015
    Status: CURRENT
  • Optimal Treatment Options and Follow-up Strategies in Patients with Desmoid Tumours
    11-3 EBS: November 2013
    Status: CURRENT
  • Chemotherapy (i.e., Gemcitabine, Docetaxel Plus Gemcitabine, Doxorubicin, or Trabectedin) for Inoperable, Locally Advanced, Recurrent, or Metastatic Uterine Leiomyosarcoma
    11-11 EBS: July 2012
    Status: CURRENT
  • Imatinib Mesylate (GleevecTM) for the Treatment of Adult Patients with Unresectable or Metastatic Gastrointestinal Stromal Tumours
    11-7 EBS Version 3: June 2015
    Status: CURRENT

For Education and Information Purposes 

  • Appropriate Surgical Margins and Proper Handling of Soft Tissue Sarcoma of the Extremities
  • Sunitinib Malate for Gastrointestinal Stromal Tumour (GIST) in Imatinib Mesylate Resistant Patients
  • Liposomal Anthracyclines in the Management of Patients with HIV-positive Kaposi's Sarcoma
  • Adjuvant Chemotherapy Following Complete Resection of Soft Tissue Sarcoma in Adults
  • Multidisciplinary Specialist Care for Sarcoma
  • Doxorubicin-based Chemotherapy for the Palliative Treatment of Adult Patients with Locally Advanced or Metastatic Soft Tissue Sarcoma
  • Ifosfamide-based Combination Chemotherapy in Advanced Soft Tissue Sarcoma
  • Dose-intensive Chemotherapy with Growth Factor or Autologous Bone Marrow/Stem Cell Transplant Support in the First-line Treatment of Advanced or Metastatic Adult Soft Tissue Sarcoma
Contact:
Program in Evidence-Based Care (PEBC)
McMaster University, Juravinski Site
G Wing, 2nd Floor
711 Concession Street
Hamilton, Ontario, Canada
L8V 1C3

Phone: 905.527.4322 ext. 42822
Fax: 905.526.6775
Email: ccopgi@mcmaster.ca
Last modified: Fri, May 06, 2016
cancer care ontario | action cancer ontario   620 University Avenue Toronto Ontario, Canada M5G 2L7   Phone: 416.971.9800 Fax: 416.971.6888

Please help improve the quality of our website by answering 10 brief questions in our online survey. Would you like to participate?

YesNo